Experience and dedication to research have made DiaSorin a leading company in the expanding market of autoimmune diagnostics. DiaSorin offers a complete line of quality Enzyme Linked Immunosorbent Assays (ELISA), Immunofluorescent Assay (IFA) and some Chemiluminescence immunoassays (CLIA).
The ELISA line encompasses a broad range of tests used in rheumatology, gastroenterology and in diagnosis of thrombosis and vasculitis. Quality-controlled manufacturing ensures high performance of the kits throughout their long shelf life. Results are obtained quickly due to simple test procedures, short incubation time, ready-to-use reagents, which are often common to several tests. The use of recombinant, purified antigens ensures high performance for routine laboratory work. EIA tests are fully automated with standardized procedures on ETI-MAX 3000 Equipment. DiaSorin immunofluorescent tests provide a choice of high-quality substrates (Hep-2 cells, Crithidiae luciliae, stomach, kidney, rat liver, neutrophil, granulocytes, pancreas and primate thyroid) for diagnosis of both systemic and organ-specific autoimmune pathologies. DiaSorin IFA screening allows clear and easy histological pattern differentiation.
The LIAISON® ANA Screen assay uses chemiluminescent immunoassay (CLIA) technology for the collective qualitative determination of autoantibodies directed against the following antigens: double-stranded DNA (dsDNA), RNP/Sm (70 kDa), SSA (Ro) (rich in 60 kDa), SS-B (La), Scl-70, Jo-1, centromere (CENP-B) and mitochondria in human serum or plasma, along with detection of sera positive for HEp-2 immunofluorescence antibody test. This test is intended as an aid in the diagnosis of connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic sclerosis (Ssc), idiopatic polymyositis (PM), dermatomyositis (DM) and CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly and telangiectasia). The test has to be performed on the LIAISON® Analyzer.
The LIAISON® dsDNA assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of autoantibodies of IgG class directed against double-stranded DNA (dsDNA) in human serum or plasma samples. The test has to be performed on the LIAISON® Analyzer.
The LIAISON® tTG IgA assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of autoantibodies of IgA class directed against tissue transglutaminase (tTG) in human serum or plasma. The presence of IgA autoantibodies to tissue transglutaminase, in conjunction with other laboratory tests and clinical findings may aid in the diagnosis and monitoring of coeliac disease (gluten-sensitive enteropathy). The test has to be performed on the LIAISON® Analyzer.
The LIAISON® ENA Screen assay uses chemiluminescent immunoassay (CLIA) technology for the collective qualitative determination of autoantibodies directed against the following extractable nuclear antigens (ENA): RNP/Sm, SS-A (Ro), SSB (La), Scl-70, Jo-1 and centromere (CENP-B) in human serum or plasma samples. The test has to be performed on the LIAISON® Analyzer.
The LIAISON® Cardiolipin IgG assay uses chemiluminescent immunoassay (CLIA) technology for the in vitro semi-quantitative determination of autoantibodies of IgG class directed against cardiolipin in human serum or plasma samples. The test has to be performed on the LIAISON® Analyzer.
The LIAISON® Cardiolipin IgM assay uses chemiluminescent immunoassay (CLIA) technology for the in vitro semiquantitative determination of autoantibodies of IgM class directed against cardiolipin in human serum or plasma samples. The test has to be performed on the LIAISON® Analyzer.
Autoimmune Diseases or Disorders result from a hyperactive immune system attacking normal tissues as if they were foreign organisms.
The National Institutes of Health (NIH) estimates up to 23.5 million Americans suffer from autoimmune disease and that the prevalence is rising. Researchers have identified 80-100 different autoimmune diseases and suspect at least 40 additional diseases of having an autoimmune basis. These diseases are chronic and can be life-threatening. Autoimmune disease is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age.
